Reaction

Terminal Insomnia reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,713 reports · 54 co-occurring drugs

As of the last recalculation, Terminal Insomnia appears in 1,713 FAERS reports alongside 54 co-occurring drug terms. The strongest observed disproportionality signal is SODIUM OXYBATE (PRR 73.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Sodium Oxybate	323	73.1	73.5
Ciclesonide	36	32.8	32.9
Calcium, Magnesium, Potassium, And Sodium Oxybates	20	28.5	28.6
Suvorexant	18	17.0	17.1
Armodafinil	28	16.4	16.4
Omalizumab	101	15.2	15.3
Modafinil	39	15.0	15.0
Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate And Amphetamine Aspartate	48	14.4	14.4
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, And Amphetamine Sulfate	41	14.4	14.4
Dexlansoprazole	47	14.1	14.1
Fentanyl Citrate	20	13.7	13.8
Methylphenidate Hydrochloride	62	13.2	13.2
Ipratropium Bromide	36	12.5	12.5
Vilazodone Hydrochloride	9	11.9	11.9
Fluticasone Furoate And Vilanterol Trifenatate	32	11.0	11.0
Fluticasone Propionate Nasal	26	10.6	10.6
Cariprazine	8	10.5	10.5
Quetiapine Fumarate	25	10.4	10.4
Rotigotine	12	10.1	10.2
Lurasidone Hydrochloride	16	9.4	9.4
Montelukast Sodium	89	9.3	9.3
Progesterone	17	9.1	9.1
Oxcarbazepine	24	9.1	9.1
Tretinoin	6	9.0	9.0
Cetiirizine	30	8.7	8.7
Lisdexamfetamine Dimesylate	23	8.6	8.6
Ziprasidone Mesylate	10	8.6	8.6
Budesonide And Formoterol Fumarate Dihydrate	64	8.3	8.3
Niraparib	14	7.7	7.7
Desvenlafaxine Succinate	17	7.7	7.7
Vibegron	5	7.6	7.6
Atomoxetine Hydrochloride	14	7.2	7.2
Levodopa	7	7.1	7.1
Varenicline Tartrate	45	7.0	7.0
Ziprasidone	10	6.9	6.9
Golimumab	46	6.7	6.7
Mepolizumab	26	6.4	6.4
Carbidopa And Levodopa	23	6.0	6.0
Hydromorphone Hydrochloride	43	5.8	5.8
Diclofenac Potassium, Film Coated	4	5.8	5.8
Diclofenac Potassium Tablets	4	5.8	5.8
Diclofenac Potassium	5	5.6	5.6
Methylphenidate	13	5.5	5.5
Apalutamide	5	5.2	5.2
Brexpiprazole	7	5.1	5.1
Botulinum Toxin Type A	5	4.9	4.9
Secukinumab	53	4.1	4.1
Elexacaftor, Tezacaftor, And Ivacaftor	4	3.9	3.9
Rimegepant Sulfate	4	3.8	3.8
Dornase Alfa	6	3.7	3.7
Lutetium Lu 177 Vipivotide Tetraxetan	4	3.7	3.7
Onabotulinumtoxina	19	3.0	3.0
Pimavanserin Tartrate	9	2.0	2.0
Valbenazine	3	1.4	1.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.